Full Text
The Full Text of this article is available as a PDF (212.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bigio I. J., Bown S. G., Briggs G., Kelley C., Lakhani S., Pickard D., Ripley P. M., Rose I. G., Saunders C. Diagnosis of breast cancer using elastic-scattering spectroscopy: preliminary clinical results. J Biomed Opt. 2000 Apr;5(2):221–228. doi: 10.1117/1.429990. [DOI] [PubMed] [Google Scholar]
- Brown N. S., Jones A., Fujiyama C., Harris A. L., Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 2000 Nov 15;60(22):6298–6302. [PubMed] [Google Scholar]
- Carragher N. O., Fincham V. J., Riley D., Frame M. C. Cleavage of focal adhesion kinase by different proteases during SRC-regulated transformation and apoptosis. Distinct roles for calpain and caspases. J Biol Chem. 2000 Nov 7;276(6):4270–4275. doi: 10.1074/jbc.M008972200. [DOI] [PubMed] [Google Scholar]
- Greco O., Folkes L. K., Wardman P., Tozer G. M., Dachs G. U. Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther. 2000 Nov;7(11):1414–1420. doi: 10.1038/sj.cgt.7700258. [DOI] [PubMed] [Google Scholar]
- Grob J. J., Dreno B., de la Salmonière P., Delaunay M., Cupissol D., Guillot B., Souteyrand P., Sassolas B., Cesarini J. P., Lionnet S. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998 Jun 27;351(9120):1905–1910. doi: 10.1016/s0140-6736(97)12445-x. [DOI] [PubMed] [Google Scholar]
- Malik K., Brown K. W. Epigenetic gene deregulation in cancer. Br J Cancer. 2000 Dec;83(12):1583–1588. doi: 10.1054/bjoc.2000.1549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Malik K., Salpekar A., Hancock A., Moorwood K., Jackson S., Charles A., Brown K. W. Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor. Cancer Res. 2000 May 1;60(9):2356–2360. [PubMed] [Google Scholar]
- Marriott J. B., Muller G., Dalgleish A. G. Thalidomide as an emerging immunotherapeutic agent. Immunol Today. 1999 Dec;20(12):538–540. doi: 10.1016/s0167-5699(99)01531-5. [DOI] [PubMed] [Google Scholar]
- Maxwell P. H., Dachs G. U., Gleadle J. M., Nicholls L. G., Harris A. L., Stratford I. J., Hankinson O., Pugh C. W., Ratcliffe P. J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104–8109. doi: 10.1073/pnas.94.15.8104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pignon J. P., Bourhis J., Domenge C., Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000 Mar 18;355(9208):949–955. [PubMed] [Google Scholar]
- Plumb J. A., Strathdee G., Sludden J., Kaye S. B., Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000 Nov 1;60(21):6039–6044. [PubMed] [Google Scholar]
- Strathdee G., MacKean M. J., Illand M., Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999 Apr 8;18(14):2335–2341. doi: 10.1038/sj.onc.1202540. [DOI] [PubMed] [Google Scholar]
- Sturla L. M., Westwood G., Selby P. J., Lewis I. J., Burchill S. A. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma. Cancer Res. 2000 Nov 1;60(21):6160–6170. [PubMed] [Google Scholar]